This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In what appears to be its Series B round, cell therapies developer Rubius Therapeutics Inc. raised $120mm in a highly oversubscribed private financing to 16 investors. The company will use the funds for ongoing development of its Red-Cell Therapeutics, a new class of compounds with potential for treating cancer, autoimmune disease, hemophilia, infectious diseases, and metabolic disorders. Clinical trials should commence in 2018. It will also use some money to expand its team.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?